18 April 2018 - - Valencia, California-based regenerative medicine company Avita Medical's (ASX: AVH; OTCQX: AVMXY) pivotal, controlled clinical trial in the treatment of deep full-thickness (third-degree) burns with the Recell autologous cell harvesting device has achieved its co-primary endpoints, demonstrating a statistically significant reduction in donor skin requirements versus standard of care while achieving comparable definitive wound closure, the company said.
The results, presented at the American Burn Association 50th annual meeting in Chicago, described the outcomes from the controlled clinical trial conducted at seven US burn centers.
According to the company, the Recell device is an investigational medical device designed to enable medical professionals to produce, at the point-of-care, a 'regenerative epidermal suspension' using a small sample of the patient's own skin. '
The autologous suspension contains cells necessary to regenerate epidermis and provides a new way to achieve permanent closure in burns and other wounds while reducing the amount of skin harvested at the time of surgery.
During the trial, the patient donor skin required to be harvested to treat burn sites with the Recell Device was 32% less than the amount harvested to treat burn sites with the standard of care (p